Letrozole is an effective option in the treatment of early-stage or advanced breast cancer in postmenopausal women
- 25 Downloads
Letrozole, a highly specific, nonsteroidal third-generation aromatase inhibitor, is a potent inhibitor of estrogen synthesis that is of benefit to postmenopausal breast cancer patients. Extended adjuvant therapy with letrozole 2.5 mg/day improves disease-free survival in early breast cancer previously treated with tamoxifen; as neoadjuvant therapy, it is superior to tamoxifen. In advanced breast cancer, letrozole 2.5 mg/day is superior to tamoxifen 20 mg/day as first-line therapy, and as effective as anastrozole 1 mg/day and at least as effective as megestrol acetate 160 mg/day as second-line therapy. Letrozole is tolerated at least as well as tamoxifen, anastrozole or megestrol acetate.
Postmenopausal breast cancer common
- 7.Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003 Jun 1; 21(11): 2101–9PubMedCrossRefGoogle Scholar
- 8.Mouridsen H, Sun Y, Gershanovich M, et al. Significantly longer time to progression for Femara (letrozole) in patients with or without prior adjuvant tamoxifen: updated analysis of the double-blind, randomized, multinational phase III trial of letrozole compared to tamoxifen as first-line hormonal therapy for advanced breast cancer [abstract no. 256]. 25th Annual San Antonio Breast Cancer Symposium; 2002 Dec 11–14; San AntonioGoogle Scholar
- 13.Novartis Oncology. About Femara: European summary of product characteristics [online]. Available from URL: http://www.femara.com [Accessed 2004 Sep 2]
- 14.Novartis Oncology. Femara prescribing information [online]. Available from URL: http://www.us.femara.com [Accessed 2004 Sep 2]